Lexicon Pharmaceuticals LXRX Business Segments — Total Costs & Expenses

Similar metrics at other companies

ARDXReportable Segment — Total Costs & Expenses

$127.27M+15.2%

TARSReportable Segment — Total Costs & Expenses

$168.18M+60.8%

UEReportable Segment — Total Costs & Expenses

$48.46M+11.7%

CONReportable Segment — Total Costs & Expenses

$448.87M+12.8%

TWSTReportable Segment — Total Costs & Expenses

$156.58M+16.5%

PCRXReportable Segment — Total Costs & Expenses

$170.47M+2.1%

Questions, answered.

What is Lexicon Pharmaceuticals's business segments — total costs & expenses?

Lexicon Pharmaceuticals (LXRX) reported business segments — total costs & expenses of $22.1M in Q1 2026.

How has Lexicon Pharmaceuticals's business segments — total costs & expenses changed year-over-year?

Lexicon Pharmaceuticals's business segments — total costs & expenses decreased by 18.0% year-over-year, from $26.94M to $22.1M.

What is the long-term trend for Lexicon Pharmaceuticals's business segments — total costs & expenses?

Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — total costs & expenses has grown at a -0.7% compound annual growth rate (CAGR), from $100.9M to $98.71M.

What does business segments — total costs & expenses mean?

The aggregate of all operating costs incurred by the business segment, including cost of sales, R&D, and administrative overhead. This metric provides a comprehensive view of the total capital required to sustain the segment's operations. Comparing this to segment revenue reveals the overall cost structure and operational sustainability.